A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma
Authors:
- 1 December 2015
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 220, 503-514
Abstract
No abstract availableKeywords
Funding Information
- Oregon State University
This publication has 51 references indexed in Scilit:
- In vitro dissolution testing strategies for nanoparticulate drug delivery systems: recent developments and challengesDrug Delivery and Translational Research, 2013
- The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticlesInternational Journal of Nanomedicine, 2012
- Differential Uptake of Functionalized Polystyrene Nanoparticles by Human Macrophages and a Monocytic Cell LineACS Nano, 2011
- A Novel Histochemical Method for a Simultaneous Staining of Melanin and Collagen FibersJournal of Histochemistry & Cytochemistry, 2011
- RXRα Ablation in Epidermal Keratinocytes Enhances UVR-Induced DNA Damage, Apoptosis, and Proliferation of Keratinocytes and MelanocytesJournal of Investigative Dermatology, 2011
- Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4‐activated invasive melanomasPigment Cell & Melanoma Research, 2010
- Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapiesExpert Opinion on Drug Delivery, 2009
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- Nanoparticle Technology for Drug Delivery Across the Blood-Brain BarrierDrug Development and Industrial Pharmacy, 2002
- Radionuclide-labelled liposomes—A new lymph node imaging agentInternational Journal of Nuclear Medicine and Biology, 1979